{
  "resourceType": "ClinicalUseDefinition",
  "id": "example-indication",
  "text": {
    "status": "extensions",
    "div": "\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\u003cp\u003e\u003cb\u003eGenerated Narrative: ClinicalUseDefinition\u003c/b\u003e\u003ca name\u003d\"example-indication\"\u003e \u003c/a\u003e\u003c/p\u003e\u003cdiv style\u003d\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"\u003e\u003cp style\u003d\"margin-bottom: 0px\"\u003eResource ClinicalUseDefinition \u0026quot;example-indication\u0026quot; \u003c/p\u003e\u003c/div\u003e\u003cp\u003e\u003cb\u003eStructureDefinition Work Group\u003c/b\u003e: brr\u003c/p\u003e\u003cp\u003e\u003cb\u003etype\u003c/b\u003e: indication\u003c/p\u003e\u003cp\u003e\u003cb\u003esubject\u003c/b\u003e: \u003ca href\u003d\"medicinalproductdefinition-example.html\"\u003eMedicinalProductDefinition/example\u003c/a\u003e\u003c/p\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003eindication\u003c/b\u003e\u003c/p\u003e\u003ch3\u003eDiseaseSymptomProcedures\u003c/h3\u003e\u003ctable class\u003d\"grid\"\u003e\u003ctr\u003e\u003ctd style\u003d\"display: none\"\u003e-\u003c/td\u003e\u003ctd\u003e\u003cb\u003eConcept\u003c/b\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd style\u003d\"display: none\"\u003e*\u003c/td\u003e\u003ctd\u003ePrevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. \u003cspan style\u003d\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"\u003e (indicationasdisease-symptom-procedure#Pulmonary-embolism-and-thrombosis-example-code)\u003c/span\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/table\u003e\u003ch3\u003eDiseaseStatuses\u003c/h3\u003e\u003ctable class\u003d\"grid\"\u003e\u003ctr\u003e\u003ctd style\u003d\"display: none\"\u003e-\u003c/td\u003e\u003ctd\u003e\u003cb\u003eConcept\u003c/b\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd style\u003d\"display: none\"\u003e*\u003c/td\u003e\u003ctd\u003eRecurrent \u003cspan style\u003d\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"\u003e (diseasestatus#Recurrent)\u003c/span\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/table\u003e\u003ch3\u003eIntendedEffects\u003c/h3\u003e\u003ctable class\u003d\"grid\"\u003e\u003ctr\u003e\u003ctd style\u003d\"display: none\"\u003e-\u003c/td\u003e\u003ctd\u003e\u003cb\u003eConcept\u003c/b\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd style\u003d\"display: none\"\u003e*\u003c/td\u003e\u003ctd\u003ePRYLX \u003cspan style\u003d\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"\u003e (intendedeffect#PRYLX)\u003c/span\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/table\u003e\u003c/blockquote\u003e\u003cp\u003e\u003cb\u003epopulation\u003c/b\u003e: \u003ca name\u003d\"group\"\u003e \u003c/a\u003e\u003c/p\u003e\u003cblockquote\u003e\u003cp/\u003e\u003cp\u003e\u003ca name\u003d\"group\"\u003e \u003c/a\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003etype\u003c/b\u003e: person\u003c/p\u003e\u003cp\u003e\u003cb\u003emembership\u003c/b\u003e: definitional\u003c/p\u003e\u003ch3\u003eCharacteristics\u003c/h3\u003e\u003ctable class\u003d\"grid\"\u003e\u003ctr\u003e\u003ctd style\u003d\"display: none\"\u003e-\u003c/td\u003e\u003ctd\u003e\u003cb\u003eCode\u003c/b\u003e\u003c/td\u003e\u003ctd\u003e\u003cb\u003eValue[x]\u003c/b\u003e\u003c/td\u003e\u003ctd\u003e\u003cb\u003eExclude\u003c/b\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd style\u003d\"display: none\"\u003e*\u003c/td\u003e\u003ctd\u003eage-range \u003cspan style\u003d\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"\u003e (characteristic#age-range)\u003c/span\u003e\u003c/td\u003e\u003ctd\u003e18-? a\u003c/td\u003e\u003ctd\u003efalse\u003c/td\u003e\u003c/tr\u003e\u003c/table\u003e\u003c/blockquote\u003e\u003c/div\u003e"
  },
  "contained": [
    {
      "resourceType": "Group",
      "id": "group",
      "type": "person",
      "membership": "definitional",
      "characteristic": [
        {
          "code": {
            "coding": [
              {
                "system": "http://ema.europa.eu/example/characteristic",
                "code": "age-range"
              }
            ]
          },
          "valueRange": {
            "low": {
              "value": 18,
              "unit": "a"
            }
          },
          "exclude": false
        }
      ]
    }
  ],
  "extension": [
    {
      "url": "http://hl7.org/fhir/StructureDefinition/structuredefinition-wg",
      "valueCode": "brr"
    }
  ],
  "type": "indication",
  "subject": [
    {
      "reference": "MedicinalProductDefinition/example"
    }
  ],
  "indication": {
    "diseaseSymptomProcedure": {
      "concept": {
        "coding": [
          {
            "system": "http://ema.europa.eu/example/indicationasdisease-symptom-procedure",
            "code": "Pulmonary-embolism-and-thrombosis-example-code"
          }
        ],
        "text": "Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults."
      }
    },
    "diseaseStatus": {
      "concept": {
        "coding": [
          {
            "system": "http://ema.europa.eu/example/diseasestatus",
            "code": "Recurrent"
          }
        ]
      }
    },
    "intendedEffect": {
      "concept": {
        "coding": [
          {
            "system": "http://ema.europa.eu/example/intendedeffect",
            "code": "PRYLX"
          }
        ]
      }
    }
  },
  "population": [
    {
      "reference": "#group"
    }
  ],
  "meta": {
    "tag": [
      {
        "system": "http://terminology.hl7.org/CodeSystem/v3-ActReason",
        "code": "HTEST",
        "display": "test health data"
      }
    ]
  }
}